Curatis Holding AG (XSWX:CURN) Other Operating Expense: CHF4.25 Mil (TTM As of Dec. 2025)


XSWX:CURN Curatis Holding AG XSWX:CURN
31 GF Score
Price CHF24.50
! 7 Warning Signs
View Full Analysis

What is Curatis Holding AG Other Operating Expense?

Curatis Holding AG XSWX:CURN +6.52% 31 Other Operating Expense is CHF4.25 Mil as of Dec. 2025. GuruFocus rates XSWX:CURN with a GF Score™ of 31/100. The stock has 7 warning signs investors should review.

Curatis Holding AG's Other Operating Expense for the six months ended in Dec. 2025 was CHF2.35 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF4.25 Mil.

Curatis Holding AG's quarterly Other Operating Expense increased from Dec. 2024 (CHF0.81 Mil) to Jun. 2025 (CHF1.90 Mil) and increased from Jun. 2025 (CHF1.90 Mil) to Dec. 2025 (CHF2.35 Mil).

Curatis Holding AG's annual Other Operating Expense increased from Dec. 2023 (CHF1.53 Mil) to Dec. 2024 (CHF4.30 Mil) but then declined from Dec. 2024 (CHF4.30 Mil) to Dec. 2025 (CHF2.98 Mil).

Curatis Holding AG Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Curatis Holding AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curatis Holding AG Other Operating Expense Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
0.00 -0.85 1.53 4.30 2.98

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 3.72 0.81 1.90 2.35
XSWX:CURN
31GF Score
Curatis Holding AG XSWX:CURN
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curatis Holding AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF4.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF4.25 Mil mean?
Curatis Holding AG (XSWX:CURN) has a Other Operating Expense of CHF4.25 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Curatis Holding AG and its competitors.
Is Curatis Holding AG's Other Operating Expense too high?
Curatis Holding AG's current Other Operating Expense is CHF4.25 Mil. Overall, Curatis Holding AG has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Other Operating Expense compare to ZTS and UTHR?
Curatis Holding AG's Other Operating Expense of CHF4.25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Curatis Holding AG and its competitors. Curatis Holding AG's current Other Operating Expense is CHF4.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Other Operating Expense of CHF4.25 Mil. The current Other Operating Expense is CHF4.25 Mil. Curatis Holding AG's overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Other Operating Expense is CHF4.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curatis Holding AG Business Description

Other Exchanges CURNz:UK0QNS:UK26U:Germany
Address Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
31GF Score

Get the complete analysis for XSWX:CURN

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF24.50
Price